NCT06272409View on ClinicalTrials.gov

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

March 15, 2025

Study Completion Date

April 15, 2027

Conditions
Allergic Rhinitis
Interventions
DRUG

DEP114

DEP114 oral solution

DRUG

Desloratadine 0.5 MG/ML

Desloratadine oral solution

Sponsors

Lead Sponsor

EMS
All Listed Sponsors
lead

EMS

INDUSTRY